Summary

Denosumab is a fully human monoclonal antibody that binds to and inhibits RANK Ligand (RANKL), a key mediator of osteoclast formation, function, and survival. This article discusses an ongoing, double-blind, placebo-controlled, phase 2 study was conducted to determine if denosumab treatment could reduce the progression of bone erosions in patients with RA who were on background methotrexate.